Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 6, 2011, Pages 760-766

  Andersen, Ellen Sloth ^a   Weiland, Ola ^b   Leutscher, Peter ^c   Krarup, Henrik ^d   Westin, Johan ^e   Moessner, Belinda ^f   Konopski, Zbigniew ^g   Frigstad, Svein Oskar ^g   Kjær, Mette ^h   Christensen, Peer Brehm ^f   Weis, Nina ^a,i  

^a HVIDOVRE HOSPITAL   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h Rigshospitalet   (Denmark)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cirrhosis; hepatitis B; nucleoside analogs; transient elastography

Indexed keywords

NUCLEOSIDE ANALOG;

ADULT; ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; DISEASE CLASSIFICATION; ELASTOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; VIROLOGY;

ADENINE; ADULT; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS B; HUMANS; LAMIVUDINE; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS;

EID: 79955960033     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2011.565068     Document Type: Article

References (30)

1. WHO: fact sheet N204: Hepatitis B. World Health Organization; 2008.
2. Lok AS, McMahon B. Chronic Hepatitis B: update 2009. Hepatology 2009;50:661-2.
3. Wands JR. Prevention of hepatocellular carcinoma. N Engl J Med 2004;351:1567-70. (Pubitemid 39315325)
4. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40: 883-91. (Pubitemid 39288121)
5. Benyon RC, Iredale JP. Is liver fibrosis reversible? Gut 2000; 46:443-6.
6. Bonis PAL, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med 2000;344:452-4.
7. Dienstag J, Goldin RD, Heathcote EJ, Hann HWL, Wessner M, Stephenson S, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105-17. (Pubitemid 36055344)
8. Mössner BK, Biagini M, Pedersen C, Christensen PB. Regression of cirrhosis of the liver detected by elastiometry. Scand J Gastroenterol 2008;43:1401-2.
9. Lai C-L, Shouval D, Lok AS, Chang T-T, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20. (Pubitemid 43357805)
10. Wu IC, Lai CL, Han SB, Han KH, Gordon S, Chao YC, et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010;51: 1185-9.
11. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93.
12. Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol 2010;52:791-9.
13. Enomoto M, Mori M, Ogawa T, Fujii H, Kobayashi S, Iwai S, et al. Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression liver stiffness during entecavir therapy. Hepatol Res 2010; 40:853-61.
14. Friedrich-Rust M, Ong M-F, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134:960-74.
15. Ganne-Carrié N, Ziol M, de Lédinghen V, Douvin C, Marcellin P, Castéra L, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006;44:1511-17. (Pubitemid 44953656)
16. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009;29:242-7.
17. Sandrin L, Fourquet B, Hasquenoph J-M, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Bio 2003;29:1705-13. (Pubitemid 38091720)
18. Krarup H, Andersen S, Madsen PH, Okkels H, Hvingel BH, Laurberg P. Benign course of long-standing hepatitis B virus infection among Greenland Inuit? Scand J Gastroenterol 2008;43:334-43. (Pubitemid 351238365)
19. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968-73. (Pubitemid 46999083)
20. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigenpositive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997;26:1338-42. (Pubitemid 27509322)
21. Vigano M, Massironi S, Lampertico P, Lavarone M, Paggi S, Pozzi R, et al. Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. Eur J Gastroenterol Hepatol 2010;22:180-4.
22. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2009;24: 1002-7.
23. Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Vir Hepatit 2007;14:360-9. (Pubitemid 46587854)
24. Schiff ER, Simsek H, Lee WM, Chao Y-C, Sette H, Janssen H, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008;103: 2776-83.
25. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann H-W, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63. (Pubitemid 29489740)
26. Lai CL, Chien RN, Leung N, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8. (Pubitemid 28304879)
27. Gish RG, Lok AS, Chang TT, de Man RA, Gadana A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44. (Pubitemid 350029745)
28. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7. (Pubitemid 26157437)
29. Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N. Quantitative analysis of HBsAg, IgM anti HBc and anti HBc avidity in acute and chronic hepatitis B. J Clin Vir 2006;37:206-12. (Pubitemid 44559777)
30. Liaw YF, Sung J, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.